RxSight, Inc. is a company engaged in the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery. The company also provides capital equipment that works in conjunction with these lenses. RxSight's products are primarily used in the medical field to enhance the efficiency and effectiveness of cataract treatments.
- Light Adjustable Lenses (LALs) - Used in cataract surgeries, these lenses are held at customer sites on consignment and revenue is recognized upon implantation in a patient.
- Light Delivery Devices (LDDs) - Deliver light to the LALs to adjust the lens post-surgery, with revenue recognized upon installation and customer acceptance.
- Service Warranty, Service Contracts, and Accessories - Provides ongoing support and additional products, with revenue recognized over the service period.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Ron Kurtz ExecutiveBoard | President and Chief Executive Officer | Ron Kurtz, M.D. has served as the President and Chief Executive Officer of RxSight since 2016 and as a Board Member from that year, demonstrating his leadership experience in the medical device field. | View Report → | |
Eric Weinberg Executive | Co-President and Chief Commercial Officer | Eric Weinberg has served as Co-President and Chief Commercial Officer at RxSight, Inc. since his promotion on July 15, 2024. Prior to that, he joined as Chief Commercial Officer in June 2015 and has held various executive roles at companies including LenSx Lasers, Alcon LenSx, and IntraLase Corp. | ||
Ilya Goldshleger Executive | Co-President and Chief Operating Officer | Ilya Goldshleger is the Co-President and Chief Operating Officer at RxSight, Inc. since July 15, 2024 and has served as Chief Operating Officer since June 2019, after joining as Vice President of Engineering in September 2015 to drive the development of innovative ophthalmic technology. | ||
Shelley Thunen Executive | Co-President and Chief Financial Officer | Board member and audit committee chair at Surface Ophthalmics, Inc. since August 2020; Board member and audit committee chair at Aeon Biopharma, Inc. since June 2023; Board member, audit committee chair, and compensation committee member at LENZ Therapeutics, Inc. since November 2023 | Shelley Thunen serves as Co-President and Chief Financial Officer at RxSight, having joined the company in January 2016 (became CFO in February 2017) and previously held executive roles at Endologix, Alcon LenSx, and IntraLase. | |
J. Andy Corley Board | Chairman of the Board of Directors | Chairman of the Board at Neurolenses, Inc.; Partner at Flying L Partners | J. Andy Corley is the Chairman of the Board of Directors at RXST, serving since July 2015. He brings extensive experience in the medical device industry through leadership roles and board positions at multiple companies. | |
Julie B. Andrews Board | Board Member and Chairperson of the Audit Committee | CFO of Orthofix Medical ; Chair of the Audit Committee at Priveterra | Julie B. Andrews has served as a board member at RXST, where she was nominated as Chairperson of the Audit Committee since August 2021. She is an experienced finance leader with roles as CFO at Orthofix Medical and board leadership at Priveterra. | |
Juliet Tammenoms Bakker Board | Board Member | Board Member of Ceribell, Inc. (NASDAQ:CBLL) | Juliet Tammenoms Bakker has been a board member of RXST since June 2015. With a deep background in healthcare venture capital and corporate governance, she co-founded Longitude Capital in 2006 and has served on multiple boards, contributing to the growth of innovative medical technology companies. | |
Robert J. Palmisano Board | Board Member and Chairperson of the Compensation Committee | Chairman of the Board at Priveterra Acquisition Corp (since December 2020) | Robert J. Palmisano has served as RXST board member and Chairperson of the Compensation Committee since August 2021, bringing extensive leadership experience from previous CEO roles at Wright Medical, ev3 Inc., and IntraLase Corp. | |
Robert Warner Board | Board Member | Board Member at i Lumen Scientific; Chairman at EyeYon Medical; Board Member at GRACE | Robert Warner has served as a Board Member at RXST since August 2021, where he was also nominated to the Compensation Committee and appointed as Chair of the Governance Committee. Previously, he held senior executive roles at Alcon Laboratories from 2005 to 2018. | |
Shweta Singh Maniar Board | Board Member | Global Leader, Healthcare & Life Sciences Solutions & Strategy at Google; Board Member at Orthofix Medical Inc. | Shweta Singh Maniar has been a board member at RXST since December 2021, currently serving on the Corporate Governance and Nominating Committee. She brings extensive leadership experience from roles at Google and as a board member at Orthofix Medical Inc., among other positions. | |
Tamara R. Fountain Board | Board Member (Class III Director) | Faculty at Rush University Medical Center; Private Practice at Ophthalmology Partners, Ltd.; Board Member at Sight Sciences | Dr. Tamara R. Fountain has served as a board member and Audit Committee member at RXST since January 2022, bringing extensive expertise in ophthalmology and leadership from her academic and clinical roles. | |
William J. Link Board | Board Member | Founder and Managing Partner at Flying L Management, LLC; Managing Director and Co-Founder at Versant Ventures Management LLC; Board Member at Horizon Surgical; Board Member at Praxis Management, LLC; Board Member at Lensar, Inc.; Board Member at Tarsus Pharmaceuticals, Inc.; Board Member at Allegro Ophthalmics, LLC; Board Member at Forsight Vision 6; Board Member at TearClear Corp.; Board Member at ViaLase, Inc.; Board Member at Osanni Bio, Inc.; Board Member at EyeDura, Inc. | William J. Link, Ph.D. has served as a Board Member of RXST since November 2016, also serving on the Compensation Committee (2016-2021) and Audit Committee (2021-2024). He has an extensive background in founding and leading healthcare and venture capital firms. |
- Given the lack of a typical March uptick and your cautious view of Q2 volumes, how will you mitigate risks if the LAL volume fails to pick up in the second half as expected?
- With growing competitive pressures and pivotal macroeconomic uncertainties, can you provide more detailed plans on accelerating LAL adoption and countering the impact of competitive trialing by fixed premium lens players?
- As you reduced production in 2025 to align with revised revenue guidance despite last year’s production ramp-up, what specific cost-control initiatives are in place if inventory sales underperform in the latter half of the year?
- In light of recurring workload challenges highlighted by practices, what concrete measures are you implementing to streamline postoperative adjustments, and how will these address capacity constraints to boost overall LAL procedures?
- Given that international expansion is a market-by-market decision and upcoming regulatory approvals are underway, how do you plan to quantify and leverage premium IOL volume gains in regions like South Korea and the U.K. while managing potential tariff risks?
Research analysts who have asked questions during Rxsight Inc earnings calls.
Thomas Stephan
Stifel
4 questions for RXST
David Saxon
Needham & Company
3 questions for RXST
Steven Lichtman
Oppenheimer & Co. Inc.
3 questions for RXST
Craig Bijou
Bank of America Securities
2 questions for RXST
Lei Huang
Wells Fargo
2 questions for RXST
Lilia-Celine Lozada
JPMorgan Chase & Co.
2 questions for RXST
Robert Marcus
JPMorgan Chase & Co.
2 questions for RXST
Young Li
Jefferies
2 questions for RXST
Adam Maeder
Piper Sandler Companies
1 question for RXST
Angela Runyararo Kumirai
UBS Group
1 question for RXST
Danielle Antalffy
UBS Group AG
1 question for RXST
Larry Biegelsen
Wells Fargo & Company
1 question for RXST
Patrick Wood
Morgan Stanley
1 question for RXST
Ryan Zimmerman
BTIG
1 question for RXST
Simran Kaur
Wells Fargo & Company
1 question for RXST
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
According to Market Scope, the global cataract IOL market is highly concentrated, with the top two players accounting for approximately 75% of the total U.S. premium cataract surgery market and approximately 60% of the global manufacturer market revenue. Our competitors are significantly larger than us with greater financial, marketing, sales and personnel resources, greater brand recognition and longer operating histories. The most popular premium IOLs families approved for cataract treatment are toric and multifocal Acrysof and Tecnis IOL models. According to the Market Scope 2024 Premium Report, Alcon is one of the top IOL manufacturers, with an estimated 2024 revenue share of the world-wide premium IOL market of approximately 44%. | |
According to Market Scope, the global cataract IOL market is highly concentrated, with the top two players accounting for approximately 75% of the total U.S. premium cataract surgery market and approximately 60% of the global manufacturer market revenue. Our competitors are significantly larger than us with greater financial, marketing, sales and personnel resources, greater brand recognition and longer operating histories. The most popular premium IOLs families approved for cataract treatment are toric and multifocal Acrysof and Tecnis IOL models. According to the Market Scope 2024 Premium Report, Johnson & Johnson is one of the top IOL manufacturers, with an estimated 2024 revenue share of the world-wide premium IOL market of approximately 24%. |
Recent press releases and 8-K filings for RXST.
- Faruqi & Faruqi, LLP is investigating potential claims and has filed a federal securities class action against RxSight, Inc. for alleged violations of federal securities laws, specifically for investors who purchased securities between November 7, 2024, and July 8, 2025.
- The complaint alleges that RxSight made false and/or misleading statements by overstating demand for its products and failing to disclose "adoption challenges" and structural issues that led to declines in sales and utilization, making it unlikely to meet its fiscal year 2025 financial guidance.
- On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results showing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.
- The deadline for investors to seek the role of lead plaintiff in the federal securities class action is September 22, 2025.
- Faruqi & Faruqi, LLP is investigating RxSight, Inc. for alleged federal securities law violations, including claims that the company overstated demand and failed to disclose "adoption challenges" leading to sales declines.
- This investigation follows RxSight's preliminary Q2 2025 financial results, reported on July 8, 2025, which revealed significant declines in sales and utilization, and a reduction of its full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this announcement, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.
- Investors who suffered losses exceeding $75,000 between November 7, 2024, and July 8, 2025, are encouraged to contact the firm, with the lead plaintiff deadline set for September 22, 2025.
- Faruqi & Faruqi, LLP is investigating and has filed a federal securities class action against RxSight, Inc. (NASDAQ: RXST) on behalf of investors who purchased securities between November 7, 2024, and July 8, 2025.
- The lawsuit alleges that RxSight made false or misleading statements and/or failed to disclose "adoption challenges" and structural issues leading to sales and utilization declines, overstated product demand, and that the company was unlikely to meet its fiscal year 2025 financial guidance.
- This action follows RxSight's preliminary Q2 2025 financial results reported on July 8, 2025, which revealed significant declines in LDD sales, LAL utilization, and overall revenue, and a lowering of full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to $7.95 per share on July 9, 2025.
- The deadline for investors to seek the role of lead plaintiff in the class action is September 22, 2025.
- Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc., and a federal securities class action has been filed, alleging the company made false or misleading statements regarding its business and demand for products.
- The lawsuit claims RxSight failed to disclose "adoption challenges" and structural issues that would prevent it from meeting its fiscal year 2025 financial guidance.
- On July 8, 2025, RxSight reported preliminary Q2 2025 results with significant declines in sales and utilization, leading to a $42.5 million reduction at the midpoint of its full year 2025 guidance.
- Following this announcement, RxSight's stock price fell 37.8% to $7.95 per share on July 9, 2025.
- Investors who suffered losses exceeding $75,000 between November 7, 2024, and July 8, 2025, are encouraged to contact the firm, with the deadline to seek lead plaintiff role being September 22, 2025.
- The DJS Law Group is investigating RxSight, Inc. for securities fraud violations on behalf of investors.
- The investigation focuses on whether RxSight issued misleading statements or failed to disclose pertinent information.
- This investigation follows RxSight's Q2 2025 financial results, which reported declines in key metrics, including Light Delivery Devices (LDD) sales and total revenue.
- RxSight also lowered its full-year financial guidance, attributing the change partly to "adoption challenges" and an "LDD stall".
- On the day of the Q2 2025 financial results announcement, shares of RxSight fell by just under 38%.
- The Schall Law Firm is investigating RxSight, Inc. (NASDAQ: RXST) for potential violations of securities laws, focusing on whether the company issued false or misleading statements and/or failed to disclose pertinent information to investors.
- The investigation follows RxSight's Q2 2025 financial results, reported on July 9, 2025, which showed declines in Light Delivery Devices (LDD) sales and light adjustable intraocular lenses (LAL) utilization, alongside an overall revenue decline.
- RxSight lowered its guidance for full year 2025, attributing the LDD stall to "Adoption challenges over the last few quarters".
- Following this news, shares of RxSight fell by 37.8% on July 9, 2025.
- RxSight announced preliminary Q2 2025 revenue of approximately $33.6 million, marking a 4% decrease compared to the prior year period and an 11% decrease compared to the first quarter of 2025.
- This revenue performance was influenced by a 45% decrease in Light Delivery Device (LDD) sales to 40 units compared to Q1 2025, despite a 13% increase in Light Adjustable Lens (LAL®/LAL+®) procedure volume compared to Q2 2024.
- The company revised its full-year 2025 revenue guidance downward to a range of $120.0 million to $130.0 million, from the previous range of $160.0 million to $175.0 million.
- As of June 30, 2025, preliminary cash, cash equivalents, and short-term investments were $227.5 million, a decrease of approximately $1.8 million from March 31, 2025.